Welcome to our dedicated page for Phathom Pharmaceuticals news (Ticker: PHAT), a resource for investors and traders seeking the latest updates and insights on Phathom Pharmaceuticals stock.
Phathom Pharmaceuticals, Inc. develops and commercializes treatments for gastrointestinal diseases, with news centered on VOQUEZNA® (vonoprazan), an oral potassium-competitive acid blocker. Company updates commonly cover VOQUEZNA commercialization for GERD, prescription trends, product presentations, clinical and real-world data, and vonoprazan use with antibiotics for H. pylori infection.
Recurring announcements also address financial results, expense discipline, balance-sheet actions, and guidance tied to the company's commercial execution. Phathom's pipeline-related updates include studies evaluating VOQUEZNA in eosinophilic esophagitis and publications or conference presentations involving GERD and non-erosive reflux disease.
Phathom Pharmaceuticals (NASDAQ: PHAT) has announced a significant leadership change with the appointment of Steven Basta as President, CEO, and Board member, effective immediately. Basta replaces Terrie Curran, who is stepping down from her positions for personal reasons after five years of leadership.
The company, which focuses on developing and commercializing novel treatments for gastrointestinal (GI) diseases, views this transition as an opportunity to accelerate commercial growth. Chairman Michael Cola expressed confidence in Basta's extensive commercial expertise and track record in developing novel treatments.
Under this transition, Phathom aims to expand opportunities for their product VOQUEZNA® and enhance shareholder value. The new CEO emphasized his commitment to unlocking VOQUEZNA's full potential in addressing unmet needs in GI disease treatment.
Phathom Pharmaceuticals (NASDAQ: PHAT) has announced a partnership with actor and comedian Kenan Thompson to launch the 'GERD IS NO JOKE' campaign, raising awareness about gastroesophageal reflux disease (GERD) and their treatment VOQUEZNA® (vonoprazan).
Thompson, the longest-running SNL cast member, reveals his personal struggle with Non-Erosive GERD and his successful treatment with VOQUEZNA, the first FDA-approved potassium competitive acid blocker (PCAB) for both types of GERD. The campaign aims to reach over 65 million Americans living with GERD through multiple channels, including broadcast television, streaming platforms, and social media.
VOQUEZNA is approved for adults for:
- Relief of heartburn associated with Non-Erosive GERD
- Treatment of all severities of Erosive Esophagitis
- Relief of related heartburn
Phathom Pharmaceuticals (PHAT) reported strong Q4 and full year 2024 results for VOQUEZNA®, its gastrointestinal treatment. The company achieved $55.3 million in net revenues for 2024, including $29.7 million in Q4 (81% increase from Q3).
Key highlights include:
- Over 300,000 filled prescriptions launch-to-date (110% increase since last report)
- More than 20,000 healthcare providers have prescribed VOQUEZNA
- Commercial coverage reaching 120+ million lives (80% of U.S. commercial lives)
- Q4 2024 net loss of $74.5 million compared to $79.6 million in Q4 2023
The company plans to initiate a Phase 2 EoE trial in Q2 2025 and has launched a direct-to-consumer campaign. Cash position stands at $297.3 million as of December 31, 2024, with an additional $100 million available under term loan.
Phathom Pharmaceuticals (NASDAQ: PHAT) has announced it will host a live webcast on Thursday, March 6, 2025, at 8:30 am ET to present its fourth quarter and full year 2024 financial results along with a business update.
The company specializes in developing and commercializing treatments for gastrointestinal diseases. Their key product is vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) marketed in the US as VOQUEZNA®. The treatment is approved for heartburn associated with Non-Erosive GERD in adults, healing and maintenance of Erosive GERD, and comes in TRIPLE PAK® and DUAL PAK® combinations for H. pylori infection treatment.
Phathom Pharmaceuticals (Nasdaq: PHAT) has announced its upcoming participation in the Guggenheim Securities SMID Cap Biotech Conference. The company's management team will engage in a fireside chat on Thursday, February 6, 2025, at 10:00 am ET and conduct one-on-one meetings throughout the conference, which runs from February 5-6, 2025, in New York, NY.
The biopharmaceutical company, which specializes in developing and commercializing novel treatments for gastrointestinal (GI) diseases, will provide a live webcast of the event. Interested parties can access both the live presentation and an archived recording through the Events & Presentations section of Phathom's website. The recording will remain available for 90 days after the event's conclusion.
Phathom Pharmaceuticals (NASDAQ: PHAT) has submitted a Citizen Petition to the FDA requesting correction of Orange Book listings for VOQUEZNA tablets. The company seeks to ensure its vonoprazan tablets receive the full 10-year New Chemical Entity (NCE) exclusivity period until May 3, 2032, aligning with the exclusivity granted to VOQUEZNA TRIPLE PAK and DUAL PAK in May 2022.
The exclusivity period includes a five-year standard period for NCEs plus an additional five years under the Generating Antibiotic Incentives Now (GAIN) Act. This would prevent submission of any Abbreviated New Drug Application or 505(b)(2) New Drug Application referencing vonoprazan during this period. The FDA must respond to the petition within 180 days.
Phathom Pharmaceuticals reported strong Q3 2024 results with net revenues of $16.4 million, showing over 120% sequential quarterly increase from Q7.3 million in Q2. The company's VOQUEZNA® products reached over 143,000 prescriptions filled to date, a 138% increase since last quarter. Commercial coverage expanded to over 80% of U.S. commercial lives, covering approximately 120 million people. The prescriber base grew to more than 13,600, up 65% from previous quarter. However, net loss increased to $85.6 million compared to $43.2 million in Q3 2023, with SG&A expenses rising significantly to $76.1 million due to commercial infrastructure buildout.
Phathom Pharmaceuticals (Nasdaq: PHAT), a biopharmaceutical company specializing in gastrointestinal treatments, has announced its management team's participation in four major healthcare investor conferences. The schedule includes Guggenheim's Inaugural Healthcare Innovation Conference in Boston (Nov 12), Stifel 2024 Healthcare Conference in New York (Nov 18), Jefferies London Healthcare Conference (Nov 20), and 7th Annual Evercore HealthCONx Conference in Coral Gables (Dec 3). Live webcasts will be available for most events, with recordings accessible for 90 days on the company's website.
Phathom Pharmaceuticals (PHAT) has announced it will report its third quarter 2024 financial results and provide a business update via live webcast on Thursday, November 7, 2024, at 8:30 am ET. The company, which focuses on developing and commercializing gastrointestinal disease treatments, will make the webcast available through their investor relations website, with a recording accessible for 90 days afterward. Phathom markets VOQUEZNA® tablets for various GERD treatments and H. pylori infection through their VOQUEZNA® TRIPLE PAK® and DUAL PAK® products.
Phathom Pharmaceuticals announced presentations of VOQUEZNA® data at the American College of Gastroenterology 2024 Annual Meeting in Philadelphia. Key highlights include results from the PHALCON-NERD-201 trial evaluating on-demand VOQUEZNA treatment, which received the ACG Outstanding Research Award in the 'Esophagus' category.
The study demonstrated that all three VOQUEZNA doses (10mg, 20mg, 40mg) effectively relieved heartburn within three hours, with significant improvements noted within one hour. Additionally, a separate presentation, awarded the ACG Presidential Poster Award, showed VOQUEZNA's effectiveness in treating nocturnal GERD symptoms, with patients experiencing significantly more heartburn-free nights compared to placebo.